Get the Weekly Intelligence Brief — top committee picks every Sunday.
LH · NYSE · STOCK

Labcorp (LH) Stock Analysis

Healthcare Updated September 06, 2026
$326.92
52W $244.52 – $341.80
64/100
$26.80B
26.9
0.85
AI Committee Verdict
Buy
64/100
Conviction: High · 80% agreement · 5 analysts
-20.2%
High

Is LH Bullish or Bearish?

Bullish. Innellis AI committee rates Labcorp (LH) Buy with a composite score of 64/100 , based on 5 analysts with 80% agreement. Last updated September 06, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +10.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -9.40 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 26.4 is moderate-to-rich. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • EPS growing 33.3% YoY — Growth
  • 3 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 26.4 is moderate-to-rich — Value
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 06, 2026
Overall Committee Score
64/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 29%
of 192 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 26.4 is moderate-to-rich
Growth Analyst bullish
72 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 33.3% YoY
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
61 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 64.4 to 64.4.

Analyst-level changes:
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-09-05 to 2026-09-06 (1 day apart).

Technical Analysis

RSI (14)
42.9
Neutral
MACD Histogram
-2.179
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.40
Inside Bands
Price vs Moving Averages
EMA 9
$330.88 Below
EMA 21
$326.28 Above
EMA 50
$310.25 Above
EMA 200
$281.74 Above

Fundamental Analysis

Valuation
76
Growth
78
Profitability
38
Financial Health
84
Cash Flow
70
Valuation
P/E Ratio 26.9×
P/B Ratio 3.10×
PEG Ratio 0.81
Dividend Yield 0.88%
52W High $341.80
52W Low $244.52
Quality & Growth
ROE 1016.8%
ROA 476.6%
Gross Margin 2785.0%
Operating Margin 1127.3%
Revenue Growth YoY
Debt / Equity 0.79
AI Fundamental Assessment
P/E ratio of 26.9 (moderate relative to a 15-40x range); Price-to-book of 3.1x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.2%; Return on assets of 4.8%; Net margin of 7.0%; Gross margin of 27.8%; Current ratio of 1.80 (healthy short-term liquidity); Debt-to-equity of 0.79; Free cash flow per share is positive (14.14); Most recent quarter beat estimates by 1.4%; 3 consecutive earnings beats; EPS growth accelerating (+4.4% -> +17.4% QoQ); Average YoY EPS growth of 14.7%; Analyst estimates rising over recent quarters
Get the Full LH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime